Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Primary Peritoneal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02283658
What this trial is testing

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous Cystadenocarcinoma+6 more
Mayo Clinic 20
Not applicableLooking for participantsNCT05236686
What this trial is testing

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group 94
Early research (Phase 1)Ended earlyNCT01329549
What this trial is testing

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Who this might be right for
Ovarian Neoplasms
Boehringer Ingelheim 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Testing effectiveness (Phase 2)Ended earlyNCT01137071
What this trial is testing

Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Recepta Biopharma 29
Early research (Phase 1)Study completedNCT01940172
What this trial is testing

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Who this might be right for
Relapsed Epithelial Ovarian CancerRelapsed Primary Peritoneal CancerRelapsed Fallopian Tube Cancer
TetraLogic Pharmaceuticals 27
Testing effectiveness (Phase 2)Study completedNCT03657966
What this trial is testing

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
SOTIO a.s. 33
Large-scale testing (Phase 3)Study completedNCT01968213
What this trial is testing

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
pharmaand GmbH 564
Testing effectiveness (Phase 2)Study completedNCT02657928
What this trial is testing

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Who this might be right for
Estrogen Receptor PositivePostmenopausalRecurrent Fallopian Tube Carcinoma+3 more
Mayo Clinic 40
Early research (Phase 1)Ended earlyNCT00637390
What this trial is testing

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
University of Michigan Rogel Cancer Center 3
Large-scale testing (Phase 3)Ended earlyNCT05870748
What this trial is testing

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+2 more
Sutro Biopharma, Inc. 600
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Testing effectiveness (Phase 2)Study completedNCT01556841
What this trial is testing

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
University College, London 94
Early research (Phase 1)Study completedNCT00082823
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Early research (Phase 1)Study completedNCT01314105
What this trial is testing

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal Neoplasms
Boehringer Ingelheim 19
Early research (Phase 1)Study completedNCT03509636
What this trial is testing

Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 113